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The advent of portable echocardiography has led to screening for rheumatic heart disease (RHD) with high
disease prevalence found in many countries. Data are presented from studies from India, Africa, and New
Zealand. The natural history of subclinical echocardiographically detected RHD is the most important
research question to be answered before more widespread screening is endorsed. The 2012 World Heart
Federation (WHF) criteria for the echocardiographic diagnosis of RHD provide standardization of RHD
diagnosis, increasing the speciﬁcity for deﬁnite RHD and raising the threshold for borderline RHD. Use of
the criteria should reduce the false positive rate for minor echocardiographic changes due to physiological
valvular regurgitation. This review highlights issues of screening for RHD that are of relevance to the
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CC BY-NC-ND license.ECHOCARDIOGRAPHIC SCREENING DATA FROM
INDIA
This cross-sectional epidemiological survey, the RHEU-
MATIC (Rheumatic Heart Echo Utilization and Monitoring
Actuarial Trends in Indian Children) study [10], was
conducted in the rural primary and secondary schools, in
the Ballabgarh Block of Haryana, North India. After
obtaining institutional ethical approval, consent was taken
from principals of schools and parents of children studying
in these schools. The aim of the study was to diagnose
RHD in asymptomatic children ages 5 to 15 years, living in
rural areas, using portable echocardiography. After cluster
sampling, 6,270 children, ages 5 to 15 years were recruitedGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 197-202from various government and private schools. After a
focused history and examination, echo-Doppler was per-
formed using a bedside portable echocardiography
machine.
The modiﬁed World Health Organization (WHO)
criteria [11] deﬁne RHD using echocardiography including
fulﬁlling Doppler criteria (a regurgitant jet of >1 cm in
length, regurgitant jet in at least 2 planes, a mosaic color jet
with a peak velocity of >2.5 m/s, and jet persisting
throughout systole or diastole) associated with at least 2
morphologic signs including leaﬂet restriction, subvalvular
thickening, and valve leaﬂet thickening. Other criteria for
diagnosing “deﬁnite” RHD by echocardiography included
mitral stenosis, mitral valve involvement with aortic
regurgitation (AR) in the absence of alternative cause for
AR, and isolated mitral regurgitation with documented
history of rheumatic fever (RF). Two investigators with
experience in interpreting echocardiography separately
analyzed the images. In case of disparity, an opinion of a
third cardiologist was taken. The parents were counseled if
any abnormality was detected either during clinical ex-
amination or by echocardiography. Patients with clinical
RHD and those with moderate regurgitation on echocar-
diogram were advised to commence secondary prophy-
laxis. Patients with subclinical RHD were advised to report
sore throat, fever, or joint pain to the local health center.Results
Of the 6,270 children included, 52.65% were male with a
mean age of 10.78  2.63 years (range 5 to 15 years).
Nearly one-third (1,908) of these children were studying in
government-funded schools. Clinical examination detected
mitral regurgitation that was conﬁrmed on echocardiog-
raphy in 5 patients and the estimated prevalence of clinical197
j gREVIEW
198RHD was 0.8 per 1,000 schoolchildren. Echocardiography
diagnosed RHD in 128 cases, a prevalence of 20.4
per 1,000 schoolchildren (95% conﬁdence interval
[CI]: 16.9 to 23.9 per 1,000 children). On multivariate
analysis, older age (odds ratio [OR]: 1.93, 95% CI: 1.29
to 2.88; p ¼ 0.001), female sex (OR: 1.84, 95% CI: 1.25
to 2.72; p ¼ 0.002), and studying in a government-funded
school (OR: 1.55, 95% CI: 1.02 to 2.34; p ¼ 0.039) were
found to be independent predictors of subclinical RHD.
Thus, the prevalence of RHD is several fold higher using
echocardiographic screening. Prevalence is higher in chil-
dren who are economically less privileged.
ECHOCARDIOGRAPHIC SCREENING DATA FROM
DIFFERENT REGIONS OF AFRICA
The ﬁrst echocardiographic screening study was performed
in Kenya in 1999, demonstrating the feasibility of echo-
based screening in asymptomatic populations [12]. Since
this ﬁrst report, several studies have been conducted in
various parts of Africa [13].
Data from Mozambique
Data from Mozambique has been published [7] and has
proven to be a sentinel study in raising awareness of the
prevalence of previously undetected RHD. In brief, 2,170
children mean age 10.6 years (range 6 to 17) were
recruited randomly from 6 primary schools in the capital,
Maputo. Two-thirds of those children were from suburban
schools and one-third from urban schools. Criteria for
echocardiographic diagnosis of RHD were deﬁned as
presence of any deﬁnite evidence of mitral or aortic valve
regurgitation seen in 2 planes by Doppler echocardiogra-
phy, accompanied by at least 2 of the 3 morphologic ab-
normalities of the regurgitant valve (restricted leaﬂet
mobility, focal or generalized valvular thickening, and
abnormal subvalvular thickening).
Results The prevalence of echocardiographic RHD was
30.4 per 1,000 children compared with 2.3 per 1,000
diagnosed clinically. The prevalence was higher in girls than
in boys and in suburban than in urban children. Retro-
spective reanalyses of the same cohort using different criteria
highlighted the need for standardized deﬁnitions for diag-
nosis of subclinical disease [14] as the initial high prevalence
rates were not conﬁrmed by subsequent criteria. Their
recently proposed “simpliﬁed” criteria [15] may have merit
but should be tested prospectively against the World Heart
Federation (WHF) criteria before recommending that
other groups adopt their use.
Data from Mali
A total of 3,092 children were selected randomly living in
an urban quarter in Bamako [16]. The age range was 5 to
16 years. After physical examination, screening echocar-
diograms were performed using parasternal long- and
short-axis views and apical 4-chamber view. Thosechildren for whom the screening echocardiogram was
considered abnormal had a complete study performed and
reviewed by 2 cardiologists. Diagnostic criteria were as per
WHO guidelines [11]. Follow-up echocardiograms were
performed every 6 to 12 months.
Results Twenty-one children had deﬁnite RHD, 46
probable RHD, and 233 possible RHD. Overall, approxi-
mately 20 per 1,000 children have probable or deﬁnite
evidence of RHD by screening echocardiography [16].
Data from Uganda
A recent study conducted in Uganda reported a 2-min
screening echocardiogram of the left-sided valves by a
single operator [17]. This was followed by detailed echo-
cardiograms at a tertiary center by experienced operators.
This screening method was able to screen >200 partici-
pants per day.
Results A total of 4,869 children were screened with 25
cases detected. The overall prevalencewas 5.1 per 1,000 (95%
CI: 3.49 to 7.6), signiﬁcantly lower prevalence rate compared
with the Mozambique study. The concept of abbreviated
echocardiograms has potential, especially in rural areas where
follow-up is problematic.An immediate assessmentwould aid
immediate counseling of participants and family.
Data from Senegal
A school-based screening program [18] conducted in 2010
in Dakar, Senegal, included 2 groups of schoolchildren:
group 1 (n ¼ 1,116) were 5 to 15 years old; group 2 (n ¼
888) were 16 to 18 years old.
Results The prevalence rates in group 1 were almost one-
half those for group 2: 5.4 per 1,000 (95% CI: 2.0 to 11.7)
and 10.1 per 1,000 (95% CI: 4.6 to 19.2) concordant with
previous clinical screening programs showing higher case
detection rates in older children [19]. This study indicates
that screening age is an important consideration in planning
a screening program.
Data from Eritrea
The majority of screening programs in Africa have focused
on schoolchildren [20]. The concern regarding the high
risk of morbidity and mortality due to RHD in pregnant
women led to a screening study of pregnant women in
Keren, Eritrea, using echocardiography [21]. The study
was conducted by 2 specially trained medical students
under the supervision of an experienced cardiologist.
Results Eight of the 348 screened women had deﬁnite
RHD. This corresponds to a prevalence of 23 per 1,000
(95% CI: 7 to 39). Further studies designed to evaluate the
clinical signiﬁcance of screening for RHD in early preg-
nancy are needed.GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 197-202
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ECHOCARDIOGRAPHIC SCREENING IN NEW
ZEALAND
The results of the initial screening study of 1,274 children
ages 10 to 13 years in urban schools in a high RF preva-
lence region are reported [9]. The study used modiﬁed
WHO criteria [11] but a mitral regurgitant jet of length >2
cm was considered pathological. There was a 26 per 1,000
prevalence of deﬁnite or probable RHD and 30 per 1,000
prevalence of possible RHD using those deﬁnitions. Since
then, another 2,494 children have been screened in 3
separate rural populations and 1 urban region. Imple-
mentation of the 2012 WHF criteria [22] in the 2 most
recent regions found a 10 per 1,000 deﬁnite RHD preva-
lence and a 24 per 1,000 borderline RHD prevalence,
signiﬁcantly lower rates than those using the modiﬁed
WHO criteria. Following the initial program [9], only those
with a positive test proceed to a specialist clinical consul-
tation with auscultation [23]. The study found that a
considerable health personnel and logistical load was
required for the screening program, the clinical evaluation,
and counseling those with a positive test [23].
Another study of a control population of 400 children
in a high socioeconomic region in New Zealand did not
ﬁnd any cases of deﬁnite RHD, but 2 children with mild
mitral regurgitation met borderline RHD criteria [24]. This
study provided data about the very low, but not zero
prevalence of subclinical mild mitral regurgitation in low
RF prevalence regions.ISSUES FOR THE GLOBAL DEVELOPMENT OF RHD
SCREENING
The need to standardize RHD echocardiographic
criteria
As illustrated in this paper, the different criteria used to
deﬁne echocardiographic RHD accounts for some of the
differences of RHD prevalence [3,6e9,23] and essentially
make epidemiological comparisons invalid. In 2009, an
international RHD echocardiographic standardization
study was started with 21 investigators from 11 countries
who had by this time practical experience of screening
many thousands of cases. All available echocardiographic,
pathological, and surgical descriptions of RHD were
analyzed. The aim was to deﬁne the minimal diagnostic
criteria for a diagnosis of RHD that could be used in clinical
cardiology practice as well as for screening programs. The
results were published as the 2012 WHF criteria for
echocardiographic diagnosis of RHD [22]. The 2012 WHF
criteria for deﬁnite RHD are more speciﬁc than previous
deﬁnitions were and the threshold has been raised for
possible RHD (renamed “borderline RHD”). It was judged
that increasing the threshold for borderline RHD will
reduce the false positive rate of RHD by excluding those
with physiological mitral and aortic regurgitation. The
WHF criteria have quickly been adopted as the current
gold standard for echocardiographic screening [25,26].GLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 197-202The investigators are also undertaking a detailed interob-
server and intraobserver study of the criteria. The WHF
criteria should facilitate further echocardiographic RHD
research, such as epidemiological studies, long-term eval-
uation of the natural history of subclinical RHD, the eval-
uation of secondary prophylaxis for echocardiographically
detected RHD, and cardiology evaluation of group A
streptococcal vaccine trials.Does echocardiography meet the requirements for
a population-screening test?
At ﬁrst sight, echocardiographic screening for RHD meets
the 3 main requirements for disease screening. First, there
is a suitable condition (RHD); second, the condition is
detectable (by echocardiography); and third, it is treatable
by long-acting benzathine penicillin [25]. A more detailed
list of requirements for screening suggested by the New
Zealand National Health Committee [27] and the Council
of Europe [28] are found on their respective websites.
The ﬁrst requirement is met as most subjects positive
for RHD by echocardiography have subclinical disease,
which is latent and pre-clinical. They have the most to gain
from such a program by prevention of progressive RHD.
However, currently, we do not know the natural history of
subclinical RHD. It is known that those with an episode of
acute RF are at high risk of RHD recurrences and pro-
gression of RHD severity [1,2], but it is not known whether
an individual with RHD identiﬁed by echocardiography is
at the same risk of RHD progression and or clinical acute
RF recurrences. Roberts et al. [25] discussed this and other
aspects of echocardiography screening and concluded that
this is the most important question hindering the recom-
mendation of wider use of echocardiography screening for
RHD. It is important to be aware that in the short term,
RHD screening will increase the prevalence of RHD within
the region and additional resources will need to be allo-
cated to effectively deliver secondary prophylaxis. It fol-
lows that it is unethical to begin a screening program if
secondary penicillin delivery is not available in the region
being screened [29].
Each region should decide before screening who
should receive secondary prophylaxis. As already outlined,
in the northern region of India and in New Zealand, those
with borderline RHD by the WHF criteria [22] or possible
RHD by the WHO criteria [11], have not commenced on
penicillin. The lack of disease progression of these cate-
gories over 2 to 4 years as reported recently in 3 reports
[8,10,30] gives support to continue the policy of not rec-
ommending penicillin for borderline RHD until the natural
history of this category is known. It is still appropriate to
provide “active surveillance,” which is used for cancers that
may not progress [31,32]. Active surveillance involves
prospectively following the case through time and rescre-
ening at intervals to monitor that the disease has not
progressed. No other active intervention is offered, unless
disease progression is found. When considered as an199
TABLE 1. Differential diagnosis of mitral regurgitation in school-
aged children in regions with high prevalence of rheumatic fever
1. RHD
2. Upper limit of physiological mitral valve regurgitation
3. Congenital mitral valve prolapse or ﬂoppy mitral valve
syndrome*
4. Infective endocarditis
5. Congenital malformation of the mitral valve, for example,
double oriﬁce MV, parachute MV, hammock MV, funnel-
shaped MV, or cleft MV
6. Congenital heart disease with mitral regurgitation, for
example, primum or secundum atrial septal defect
MV, mitral valve; RHD, rheumatic heart disease.
*May be associated with abnormal body habitus, Marfan syndrome
or other connective tissue disorders; endomyocardial ﬁbrosis is
common in some countries.
TABLE 2. Differential diagnosis of aortic regurgitation in school-
aged children in regions with high prevalence of rheumatic fever
1. RHD
2. Bicuspid aortic valve with aortic regurgitation
3. Dilated aortic sinus or root
4. Infective endocarditis
RHD, rheumatic heart disease.
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approach is appealing as patients are saved the 4-weekly
intramuscular penicillin injections and the RF secondary
prophylaxis register is not inundated with cases that may
never need penicillin.
No single country to date has had the statistical power
by numbers screened and length of follow-up to answer
the question of efﬁcacy of treatment for deﬁnite RHD even
though it seems logical to treat this category. It has been
judged that a treatment RCT for deﬁnite RHD is not
feasible currently for 3 broad reasons. First, few regions
have sufﬁciently reliable secondary prophylaxis programs
that randomization to penicillin or not would be prob-
lematic. Second, intramuscular penicillin is not universally
administered due to the issues of needles/acquired immu-
nodeﬁciency syndrome/safe penicillin availability; and
third, many judge it unethical not to treat deﬁnite RHD. In
addition, many programs would not receive funding unless
those detected with RHD were treated. A case-control
study of deﬁnite RHD faces the same logistical problems
as outlined herein, especially as many groups will not
enroll if they cannot intend to treat by penicillin. A logical
next level of evidence is the use of registry data as used by
many international groups such as, International Society of
Heart and Lung Transplantation, and interventional car-
diology registries.
A prospective, international, multicenter registry of
deﬁnite and borderline RHD (known as the DeﬁneRHD
registry) is being implemented. Follow-up of secondary
penicillin status with frequent reporting (3-monthly) and
echocardiography changes (2-yearly) should answer the
question whether those with deﬁnite RHD receiving good
secondary prophylaxis will show less disease progression
and more disease regression than will those with no or
poor secondary prophylaxis. Powering allows for a 25%
difference in proportions deteriorating between the treat-
ment arms over 4 years. The signiﬁcance of the study is
that it provides a realistic chance of deﬁning the natural
history of subclinical echocardiographically detected deﬁ-
nite RHD in the shortest possible time. If the study does
not prove that those with deﬁnite RHD are at increased risk
of progression of RHD, then borderline RHD will also not
be a risk factor for RHD progression.
Observational data about RHD disease control may
also come from small well-deﬁned geographical regions
such as the Paciﬁc Islands of Tonga, Samoa, and Fiji.
Screening has continued on a regular basis in Tonga,
population 90,000, following the original study [6].
Another 11,000 children have been screened, which rep-
resents a large proportion of the country’s youth at risk of
RF (T. Fakakovikaetau, personal communication, June
2010). Due to considerations, such as the high prevalence
of RHD, the restricted access to surgery, and geographic
isolation, a decision was made to provide secondary pro-
phylaxis for those with deﬁnite and borderline changes as
well as deﬁnite RHD changes. This policy may well result
in reduced RHD disease burden in deﬁned small regions.On the other hand, in light of recent follow-up studies
[8,10,30], it is likely that minor echocardiographic changes
may have been overtreated.
Those planning RHD screening should be aware of a
wider discussion of optimal active and passive surveillance
for RHD [11] and the current controversies of screening
[25,26]. Echocardiography screening has increased the
advocacy for RF and RHD, but it has not yet proven to be
cost-effective for disease control. It may be logical for
resource-limited countries to pre-select patients with
pathological murmurs for echocardiography, allowing a
much larger population to be screened for the same dollar
value [33,34]. Sadiq et al. [33] were able to screen an
impressive 24,980 Pakistani children using this model.Issues for cardiologists
Cardiologists may be asked to review echocardiograms
from screening programs. The cardiologist should be
familiar with the differential diagnoses of rheumatic mitral
regurgitation as listed in Table 1. A mid-systolic click
associated with mitral regurgitation strongly suggests
congenital mitral valve prolapse not RHD, and congenital
mitral variants appear in about 1% of the population [9].
Physiological mitral regurgitation needs to be excluded
[8,9] to prevent overdiagnosis. Aortic regurgitation is less
of a diagnostic problem as the same echocardiogram ex-
cludes bicuspid aortic valve and a dilated aortic root asGLOBAL HEART, VOL. 8, NO. 3, 2013
September 2013: 197-202
TABLE 3. Logistical considerations for RHD echocardiographic
screening
1. RF register with secondary prophylaxis delivery structure
2. Public health, pediatric, cardiology, and community
nursing partnership
3. Cardiologists to read the abnormal echocardiograms
(ideally with second opinion capability)
4. Clinicians to counsel those with abnormalities
5. Financial cost of staff, echocardiography, secondary
prophylaxis, clinical follow-up
RF, rheumatic fever; RHD, rheumatic heart disease.
gREVIEWjcauses of aortic regurgitation (Table 2). The WHF criteria
[22] are also available on the WHF website.
The acceptability of long-term secondary prophylaxis
for those with echocardiographically detected RHD has not
been established or researched. In most regions, children
with an episode of acute RF are admitted to the hospital
with the acute illness, often with painful arthritis. This al-
lows families to understand well and accept, usually, the
importance of secondary prophylaxis. In contrast, the logic
for secondary prophylaxis may not be understood by the
family of an otherwise healthy child who is found to have
echocardiographic RHD.
Logistical issues for echocardiographic screening are
summarized in Table 3. The program will also detect cases
of congenital heart disease, which require clinical man-
agement [9].Issues for cardiac surgeons
The majority of children with RHD detected by screening
have mild disease. However, some individuals will have
severe disease and cardiac surgery may be indicated. This
must be taken into account from the outset before
screening is planned. Many regions with high prevalence of
RHD do not have access to cardiac surgery. The cardiology
community must continue to advocate for improving sec-
ondary prophylaxis, ideally through registry-based pro-
grams [11], as they remain the proven method to prevent
RHD progression [35,36].SUMMARY
Portable echocardiography is a relatively new screening
tool for RHD, which has raised awareness of the high
prevalence of RHD in many countries. Many requirements
of a screening test are met, but the natural history of
subclinical RHD needs further clariﬁcation. Use of the
2012 WHF criteria for the echocardiographic diagnosis of
RHD is strongly recommended. Cardiologists and cardiac
surgeons should help provide advocacy for improving
secondary prophylaxis programs, as this remains pivotal
for RHD control.GLOBAL HEART, VOL. 8, NO. 3, 2013
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